Immune-Related Adverse Events: A Case-Based Approach.

Area of Science:

• Oncology
• Immunology

Background:

• Immunotherapy, particularly immune checkpoint inhibitors (ICIs), has revolutionized cancer treatment.
• ICIs work by enhancing the patient's immune system to combat tumors.
• Despite improved outcomes, ICIs can lead to a wide range of immune-related adverse events (irAEs).

Purpose of the Study:

• To provide a comprehensive case-based review of common and significant irAEs.
• To detail the epidemiology, clinical presentations, and management strategies for irAEs.
• To explore future directions for irAE prevention and management.

Main Methods:

• Case-based review of common and clinically important immune-related adverse events.
• Focus on epidemiological data, clinical manifestations, and established management protocols.
• Examination of emerging strategies for irAEs.

Main Results:

• Immune checkpoint inhibitors (ICIs) are associated with a broad spectrum of immune-related adverse events (irAEs).
• Variable clinical presentations of irAEs can affect any organ system.
• Prompt identification and management of irAEs are linked to improved patient outcomes.

Conclusions:

• Immune checkpoint inhibitors (ICIs) represent a significant advancement in oncology.
• Understanding and managing immune-related adverse events (irAEs) is a critical challenge for oncologists.
• Further research into irAE prevention and management is warranted.